Effect of intracameral human cord blood-derived stem cells on lasered rabbit trabecular meshwork.
Intracameral cord blood cells
Stem cells
Trabecular meshwork
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
01
05
2018
accepted:
22
05
2019
pubmed:
30
5
2019
medline:
17
3
2020
entrez:
30
5
2019
Statut:
ppublish
Résumé
This study aimed to investigate the effect of intracameral human cord blood stem cells on lasered rabbit trabecular meshwork. Immediately following diode laser application to the trabecular meshwork, human cord blood stem cells were injected intracamerally, in one eye of 12 albino rabbits. The other eye of ten rabbits was lasered controls and two eyes were normal controls. Rabbits were killed after 4, 8 and 12 weeks. Lasered control rabbit eyes showed significant disruption of trabecular architecture, loss and pleomorphism of trabecular endothelial cells and progressive narrowing of trabecular spaces till 12 weeks. In contrast, lasered eyes, concurrently injected with human cord blood stem cells, showed relatively preserved endothelial cellularity and structure of the trabecular meshwork, at all time points. Human CD34- and CD44-positive cells were identified in 7/8 eyes treated with stem cells, at 4 and 8 weeks, and 2 of 3 at 12 weeks. Many PKH26-labeled human cord blood cells were visible throughout the trabecular area at 4 weeks. They gradually decreased in number by 8 weeks, and at 12 weeks, they appeared to be oriented along trabecular beams. There was a relative preservation of cellularity and architecture of the trabecular meshwork in eyes injected with human cord blood stem cells, as compared to lasered control eyes up to 12 weeks, without significant inflammation. This suggests a probable role for such stem cells in eyes with glaucoma, having trabecular dysfunction.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to investigate the effect of intracameral human cord blood stem cells on lasered rabbit trabecular meshwork.
METHODS
METHODS
Immediately following diode laser application to the trabecular meshwork, human cord blood stem cells were injected intracamerally, in one eye of 12 albino rabbits. The other eye of ten rabbits was lasered controls and two eyes were normal controls. Rabbits were killed after 4, 8 and 12 weeks.
RESULTS
RESULTS
Lasered control rabbit eyes showed significant disruption of trabecular architecture, loss and pleomorphism of trabecular endothelial cells and progressive narrowing of trabecular spaces till 12 weeks. In contrast, lasered eyes, concurrently injected with human cord blood stem cells, showed relatively preserved endothelial cellularity and structure of the trabecular meshwork, at all time points. Human CD34- and CD44-positive cells were identified in 7/8 eyes treated with stem cells, at 4 and 8 weeks, and 2 of 3 at 12 weeks. Many PKH26-labeled human cord blood cells were visible throughout the trabecular area at 4 weeks. They gradually decreased in number by 8 weeks, and at 12 weeks, they appeared to be oriented along trabecular beams.
CONCLUSIONS
CONCLUSIONS
There was a relative preservation of cellularity and architecture of the trabecular meshwork in eyes injected with human cord blood stem cells, as compared to lasered control eyes up to 12 weeks, without significant inflammation. This suggests a probable role for such stem cells in eyes with glaucoma, having trabecular dysfunction.
Identifiants
pubmed: 31140023
doi: 10.1007/s10792-019-01120-w
pii: 10.1007/s10792-019-01120-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2757-2766Références
Stem Cells. 2015 Mar;33(3):751-61
pubmed: 25377070
Bone Marrow Transplant. 2001 Jan;27(1):1-6
pubmed: 11244431
FASEB J. 2006 May;20(7):950-2
pubmed: 16585061
Exp Eye Res. 1986 Dec;43(6):885-94
pubmed: 3817030
Proc Natl Acad Sci U S A. 2016 Jun 21;113(25):E3492-500
pubmed: 27274060
Invest Ophthalmol Vis Sci. 2014 Dec 09;56(1):81-9
pubmed: 25491299
Indian J Ophthalmol. 2001 Dec;49(4):255-9
pubmed: 12930118
Bull World Health Organ. 2004 Nov;82(11):887-8
pubmed: 15640929
Blood. 2003 Jun 1;101(11):4233-44
pubmed: 12522002
PLoS One. 2015 Jun 24;10(6):e0128973
pubmed: 26107378
J Biol Chem. 2014 Aug 22;289(34):23465-81
pubmed: 24986866
Stem Cell Res Ther. 2015 Sep 16;6:177
pubmed: 26377305
Stem Cells. 2007 Mar;25(3):602-11
pubmed: 17053209
J Clin Invest. 2004 Sep;114(6):765-74
pubmed: 15372100
Br J Ophthalmol. 1972 Mar;56(3):157-74
pubmed: 4113454
Stem Cells. 2013 Jun;31(6):1136-48
pubmed: 23495088
Surv Ophthalmol. 2008 Nov;53 Suppl1:S3-10
pubmed: 19038621
Sci Rep. 2018 Aug 16;8(1):12251
pubmed: 30115953
J Glaucoma. 1998 Feb;7(1):45-9
pubmed: 9493115
Cytotherapy. 2012 Nov;14(10):1159-63
pubmed: 23066784
Cytotherapy. 2011 Sep;13(8):993-9
pubmed: 21671823
Arch Ophthalmol. 1992 Dec;110(12):1769-78
pubmed: 1463421
Invest Ophthalmol Vis Sci. 2013 Feb 19;54(2):1450-9
pubmed: 23341019
Croat Med J. 2009 Aug;50(4):351-60
pubmed: 19673035
Stem Cell Res Ther. 2015 Mar 14;6:29
pubmed: 25890251
Cell Transplant. 2002;11(3):265-74
pubmed: 12075992
Immunology. 2009 Feb;126(2):220-32
pubmed: 18624725
Invest Ophthalmol Vis Sci. 2002 Feb;43(2):402-10
pubmed: 11818384
Br J Ophthalmol. 2000 Jan;84(1):48-53
pubmed: 10611099
J Stem Cells Regen Med. 2010 Oct 30;6(3):175-6
pubmed: 24693165
Invest Ophthalmol Vis Sci. 2014 Oct 08;55(11):7065-72
pubmed: 25298418
Cell Biol Int. 2003;27(5):445-7
pubmed: 12758093
J Hematother. 1996 Apr;5(2):157-60
pubmed: 8723794
Exp Eye Res. 2007 Oct;85(4):557-62
pubmed: 17822700
Exp Eye Res. 2009 Apr;88(4):769-75
pubmed: 19114037
Blood. 2002 Sep 1;100(5):1611-8
pubmed: 12176879
Invest Ophthalmol Vis Sci. 2010 Apr;51(4):2051-9
pubmed: 19933193
Cytometry. 1998 Apr 15;34(2):61-70
pubmed: 9579602
Acta Neurobiol Exp (Wars). 2010;70(4):337-50
pubmed: 21196942
Cell Mol Biol (Noisy-le-grand). 2015 May 08;61(2):18-25
pubmed: 26025397